14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close May 04, 2026
EKSO vs ABPWW: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of May 04, 2026, Ekso Bionics Holdings, Inc. (EKSO) is the stronger overall head-to-head candidate over Abpro Holdings, Inc. Warrant (ABPWW) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas ABPWW carries 45.0/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EKSO vs ABPWW. Trailing 12-month operating profitability (EKSO -119.7% vs ABPWW N/A) and valuation multiples (EKSO N/M vs ABPWW N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ EKSO vs ABPWW Key Questions & Quantitative Answers
As of May 04, 2026, Ekso Bionics Holdings, Inc. (EKSO) is the stronger overall head-to-head candidate over Abpro Holdings, Inc. Warrant (ABPWW) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas ABPWW carries 45.0/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin). Technically, EKSO sits in a Markup phase (RSI 60.4, UNCLASSIFIED options structure) and ABPWW sits in a Neutral phase (RSI N/A, UNCLASSIFIED options structure).
EKSO leads the Growth & Scale pillar: EKSO posts -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin), compared with ABPWW at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, EKSO generates $13M in USD-normalized revenue versus N/A for ABPWW. In operating R&D and SG&A reinvestment, EKSO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABPWW.
EKSO screens cheaper on headline valuation multiples. EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin), whereas ABPWW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EKSO (-107.6% ROE) versus ABPWW (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk). By comparison, ABPWW carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-1.56β · 265% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of May 04, 2026. For educational research only; not investment advice.